BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Mestag Therapeutics appoints Prof. Ton Logtenberg as Chair

  Mestag Therapeutics, an immunotherapy company harnessing new insights into fibroblast-immune interactions in cancer and inflammatory disease, announced the appointment of Prof. Ton Logtenberg as Chair.

  December 20, 2022

   · 

  2 min read
• Business

  Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® with KEYTRUDA® for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

  Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV ® (enfortumab vedotin-ejfv) with KEYTRUDA ® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer.

  December 20, 2022

   · 

  59 min read
• Bio NC

  Dentsply Sirona to Present at the 41st Annual J.P. Morgan Healthcare Conference

  DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced that the company will participate in the 41st Annual J.P. Morgan Healthcare Conference.

  December 20, 2022

   · 

  1 min read
• Quest Analytics Achieves HITRUST Risk-based, 2-year Certification for Quest Enterprise Services (QES) to Manage Risk, Improve Security Posture and Meet Compliance Requirements

  Quest Analytics today announced that Quest Enterprise Services (QES) has earned Certified status for information security by HITRUST.

  December 20, 2022

   · 

  2 min read
• Drug Development

  BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

  BioLineRx Ltd. today announced results from the Phase 1/2a study of intratumoral cancer vaccine candidate, AGI-134, designed to evaluate the safety and biological activity of AGI-134 in patients with unresectable metastatic solid tumors.

  December 20, 2022

   · 

  9 min read
• Business

  Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board

  Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company’s independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022.

  December 20, 2022

   · 

  3 min read